Foundation Medicine’s pan tumor liquid biopsy test is now FDA-Approved to identify patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer who may be appropriate for treatment with LYNPARZA
San Francisco, CA (UroToday.com) — Foundation Medicine, Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®Liquid CDx to be used as a companion diagnostic for LYNPARZA® (olaparib). As a companion diagnostic, FoundationOne Liquid CDx will use a blood-based biopsy to identify patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer (mCRPC) who may be appropriate for treatment with LYNPARZA. FoundationOne Liquid CDx, Foundation Medicine’s liquid biopsy test was approved by the FDA in August to report genomic alteration results for patients with any solid tumor.